Announcements
- Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
- Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.75 |
---|---|
High | 9.75 |
Low | 9.65 |
Bid | -- |
Offer | -- |
Previous close | 9.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 60.33m |
Free float | 58.61m |
P/E (TTM) | -- |
Market cap | 639.45m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 14:29 BST.
More ▼